SPECIALTY GUIDELINE MANAGEMENT

HERCEPTIN HYLECTA (trastuzumab and hyaluronidase-oysk)

POLICY

I. INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

FDA-Approved Indications

- A. Herceptin Hylecta is indicated for adjuvant treatment of adults with HER2 overexpressing node positive or node negative (ER/PR negative or with one high risk feature) breast cancer:
 - As part of a treatment regimen consisting of doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel
 - 2. As part of a treatment regimen with docetaxel and carboplatin
 - 3. As a single agent following multi-modality anthracycline based therapy
- B. Herceptin Hylecta is indicated in adults:
 - 1. In combination with paclitaxel for first-line treatment of HER2-overexpressing metastatic breast cancer
 - 2. As a single agent for treatment of HER2-overexpressing breast cancer in patients who have received one or more chemotherapy regimens for metastatic disease

All other indications are considered experimental/investigational and are not a covered benefit.

II. CRITERIA FOR APPROVAL

Breast Cancer

Authorization of 12 months may be granted for the treatment of adjuvant early stage or metastatic HER2-overexpressing breast cancer.

III. REFERENCES

1. Herceptin Hylecta [package insert]. South San Francisco, CA: Genentech, Inc.: February 2019.

Herceptin Hylecta 3017-A SGM P2019.docx

pharmaceutical manufacturers that are not affiliated with CVS Caremark.

© 2019 CVS Caremark. All rights reserved.



This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of